EBX-102-02, A Full-Spectrum Microbiome Drug, Shows Promise for IBS-C in Phase 2a Trial

Published Date: 25 Jun 2025

EBX-102-02 was well tolerated and led to clinically meaningful improvements across multiple symptom domains in patients with IBS-C.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Aspirin Fails to Boost Survival in Colorectal Cancer Trial

2.

Do Anatomy Atlases Reflect Social Inequalities?

3.

A higher risk of chemotherapy-induced peripheral neuropathy is associated with a deficiency in vitamin D prior to treatment.

4.

Some triple negative breast cancers might be avoided by longer breastfeeding

5.

Quizartinib Benefit in AML Limited to FLT3-Mutated Subgroup


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot